NR4A1 and endometrial cancer: MPA is recommended as a fertility-preserving treatment for young endometrial cancer patients, as well as palliative treatment for terminally ill patients with hormone receptor-positive cancer, especially with PR; most of the MPA anticancer effects are known to act through the interaction with PR [20].